Brought to you by 
Servier receives option to take full IP ownership of Cortex’s CX1632
07 Oct 2011
Executive Summary
Servier SA has received an exclusive option to acquire worldwide rights to issued patents and patent applications for preclinical drug candidate CX1632 (S47445), jointly held by Cortex Pharmaceuticals Inc. (Ampakine technology that creates medicines that strengthen signals between brain cells).
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Servier receives option to take full IP ownership of Cortex’s CX1632
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice